$1.390
-0.448 (-32.20%)收盘时
GCTK 资讯
GCTK 事件
GlucoTrack Inc Trading Halted, News Pending
GlucoTrack Inc trading halted, news pending
Glucotrack Subsidiary Lokahi Launches Qare
Lokahi Therapeutics, a subsidiary of Glucotrack, announced the public launch of Qare. Launching initially in the GLP-1 category, Qare enables users to compare their self-reported results, side effects, and out-of-pocket costs against people with a similar profile. Cohort comparisons are presented in aggregate, and Qare's data infrastructure is hosted by third-party providers that maintain SOC 2 and ISO 27001 certifications.
Lokahi Therapeutics Launches Comparative Health Platform Qare
Lokahi Therapeutics announced Qare, a comparative health platform designed to evaluate treatment outcomes by comparing experiences across patients using different medications within the same therapeutic class. Introduced on National GLP-1 Day, Qare is expected to become publicly available on October 14. Launching initially in the GLP-1 category, Qare is designed to provide a platform for GLP-1 users, regardless of product, to document, organize, and analyze their treatment experiences relative to others on a similar journey. Lokahi is introducing Qare to address a significant gap in healthcare data by helping patients answer a simple but important question: "How does my treatment experience compare to others like me?" While traditional health data tools focus primarily on individual tracking and recordkeeping, Qare is designed as a comparative health platform that places treatment experiences within the context of real-world patient cohorts. Lundefinedkahi believes this approach may advance comparative health intelligence by providing greater visibility into how patients experience therapies across a treatment category. Qare is designed to empower patients to evaluate how their treatment experiences compare with those of similar patients using different medications, with the goal of creating greater accountability throughout the treatment process.
Lokahi Therapeutics Partners with Pepperdine for ai2 Pipeline Initiative
Lokahi Therapeutics will partner with Pepperdine E2B to engage students in its ai2 Pipeline initiative during the upcoming academic year. The collaboration is intended to provide students with hands-on experience evaluating real-world biopharmaceutical opportunities while supporting Lokahi's ongoing efforts to identify and assess therapeutic assets through its ai2 platform. The Pepperdine collaboration will begin with a project involving full-time MBA students in a marketing course taught by Professor Kimber Maderazzo at the Pepperdine Graziadio Business School. Through the ai2 Pipeline program, participating students will work alongside Lokahi professionals to identify, evaluate, and prioritize therapeutic opportunities. Project teams will assess scientific, regulatory, intellectual property, commercial, and strategic considerations that influence decisions across the biopharmaceutical asset lifecycle. Students will develop recommendations based on structured analysis of actual therapeutic opportunities rather than hypothetical case studies. During its first year, the ai2 Futures Lab engaged 64 students and identified more than 45 potential assets, several of which have advanced into active pipeline discussions. The program is designed to expand Lokahi's sourcing reach and analytical capacity while supporting a disciplined, capital-efficient approach to pipeline development.
Glucotrack Prices Public Offering at $2.04 per Share
Glucotrack announced the pricing of a "best efforts" public offering of 169,388 shares of common stock at a price of $2.04 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to 1,350,220 shares of common stock at a price of $2.039 per pre-funded warrant. The Company expects to receive aggregate gross proceeds of approximately $3,100,000, before deducting placement agent fees and offering expenses. The offering was priced at-the-market under Nasdaq rules. The offering is expected to close on or about September 25, 2026, subject to the satisfaction of customary closing conditions. Dawson James Securities, Inc. is acting as the sole placement agent for the public offering.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。